Πρωτεύουσες καρτέλες
Ο κατάλογος των δημοσιεύσεων είναι ενδεικτικός και μπορεί να μην περιλαμβάνει το σύνολο των δημοσιεύσεων.
Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice.
Curr Vasc Pharmacol.
(2019).
Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block..
Curr Vasc Pharmacol.
(2019).
Effects of lipid lowering drugs on arterial stiffness. One more way to reduce cardiovascular risk?.
Curr Vasc Pharmacol.
(2019).
Carotid intima-media thickness as a target-organ damage and treatment-target: Need for a major revision?.
J Clin Hypertens (Greenwich). 20(2), 255-257.
(2018).
Antihypertensive therapy in acute ischemic stroke: where do we stand?.
J Hum Hypertens. 32(12), 799-807.
(2018).
What is the role of statins in the elderly population?.
Expert Rev Clin Pharmacol. 11(4), 329-331.
(2018).
The potential role of statins in treating liver disease..
Expert Rev Gastroenterol Hepatol. 12(4), 331-339.
(2018).
Renal resistive index for renovascular hypertension: In the quest of the Holy Grail..
J Clin Hypertens (Greenwich). 20(3), 589-591.
(2018).
Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?.
J Clin Hypertens (Greenwich). 20(4), 634-636.
(2018).
Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality..
Curr Vasc Pharmacol. 16(3), 206-208.
(2018).
Pseudohyperaldosteronism due to mumijo consumption during pregnancy: a licorice-like syndrome..
Gynecol Endocrinol. 34(12), 1019-1021.
(2018).
Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?.
J Clin Hypertens (Greenwich). 20(5), 942-948.
(2018).
Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?.
Open Cardiovasc Med J. 12, 29-40.
(2018).
Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis..
Curr Vasc Pharmacol. 16(2), 104-106.
(2018).
Diabetes and lipid metabolism..
Hormones (Athens). 17(1), 61-67.
(2018).
The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data..
Hormones (Athens). 17(1), 83-95.
(2018).
Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit?.
Maturitas. 108, 45-52.
(2018).
Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?.
J Clin Hypertens (Greenwich). 20(3), 469-471.
(2018).